PE20221786A1 - Derivados de furoindazol - Google Patents
Derivados de furoindazolInfo
- Publication number
- PE20221786A1 PE20221786A1 PE2022001093A PE2022001093A PE20221786A1 PE 20221786 A1 PE20221786 A1 PE 20221786A1 PE 2022001093 A PE2022001093 A PE 2022001093A PE 2022001093 A PE2022001093 A PE 2022001093A PE 20221786 A1 PE20221786 A1 PE 20221786A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- diseases
- represents hydrogen
- inflammatory
- haloalkyl
- Prior art date
Links
- LHTSYIHIIZNLCQ-UHFFFAOYSA-N 1h-furo[2,3-g]indazole Chemical class O1C=CC2=C1C=CC1=C2NN=C1 LHTSYIHIIZNLCQ-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 230000002757 inflammatory effect Effects 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 201000004982 autoimmune uveitis Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto de formula general (I) donde: R1 representa hidrogeno, alquilo-C1-C4 o haloalquilo-C1-C4; R2 representa hidrogeno, alquilo-C1-C4 o haloalquilo-C1-C4; o R1 y R2 junto con el atomo de carbono al cual estan unidos forman un anillo cicloalquilo o heterocicloalquilo de 3 a 6 miembros; R3 representa cicloalquilo-C3-C6, heterocicloalquilo de 3 a 6 miembros, ntre otros; R4 representa hidrogeno, alquilo-C1-C4, haloalquilo-C1-C4 o cicloalquilo-C3-C6; R5, R6 representan, independientemente entre si, hidrogeno, alquilo-C1-C4, hidroxialquilo-C2-C4, entre otros, o R5 y R6 junto con el atomo de nitrogeno al cual estan unidos forman un anillo heterociclico de 3 a 6 miembros que contiene nitrogeno, que opcionalmente contiene un heteroatomo o grupo que contiene heteroatomo adicional seleccionado de O, NH y S, y que puede estar opcionalmente sustituido, R7a representa hidrogeno, deuterio o alquilo-C1-C4; R7b representa hidrogeno, deuterio o alquilo-C1-C4. Utiles para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades autoinmunes tales como esclerosis multiple, psoriasis, artritis psoriasica, artritis reumatoidea, espondilitis anquilosante, lupus eritematoso sistemico, uveitis autoinmune primaria y secundaria, trastornos inflamatorios como endometriosis, enfermedades oculares inflamatorias, enfermedades renales inflamatorias, enfermedades hepaticas inflamatorias como enfermedades hepaticas no alcoholicas, enfermedad pulmonar obstructiva cronica, y trastornos metabolicos y metabolico- endocrinos, trastornos de dolor neuropatico e inflamatorio en humanos y animales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19217856 | 2019-12-19 | ||
| PCT/EP2020/085905 WO2021122415A1 (en) | 2019-12-19 | 2020-12-14 | Furoindazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221786A1 true PE20221786A1 (es) | 2022-11-22 |
Family
ID=68965797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001093A PE20221786A1 (es) | 2019-12-19 | 2020-12-14 | Derivados de furoindazol |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230112499A1 (es) |
| EP (1) | EP4077334A1 (es) |
| JP (1) | JP2023508908A (es) |
| KR (1) | KR20220118480A (es) |
| CN (1) | CN115135656B (es) |
| AR (1) | AR120856A1 (es) |
| AU (1) | AU2020408908A1 (es) |
| BR (1) | BR112022011237A2 (es) |
| CA (1) | CA3164963A1 (es) |
| CL (1) | CL2022001644A1 (es) |
| CO (1) | CO2022008338A2 (es) |
| CR (1) | CR20220291A (es) |
| DO (1) | DOP2022000126A (es) |
| EC (1) | ECSP22047527A (es) |
| GE (1) | GEP20247585B (es) |
| IL (1) | IL293968A (es) |
| JO (1) | JOP20220156A1 (es) |
| MX (1) | MX2022007685A (es) |
| PE (1) | PE20221786A1 (es) |
| TW (1) | TW202136271A (es) |
| WO (1) | WO2021122415A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| EP4298102A1 (en) * | 2021-02-23 | 2024-01-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022194267A1 (zh) * | 2021-03-18 | 2022-09-22 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| WO2022229061A1 (en) * | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| WO2024140969A1 (zh) * | 2022-12-30 | 2024-07-04 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| AU727654B2 (en) | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| WO2001083487A1 (fr) | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de froindazole |
| WO2009023773A2 (en) * | 2007-08-15 | 2009-02-19 | University Of Miami | Galactokinase inhibitors |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| US8263610B2 (en) | 2008-12-30 | 2012-09-11 | Arqule, Inc. | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| WO2014095798A1 (en) * | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201411241D0 (en) | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016085990A1 (en) * | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN108530480B (zh) | 2017-03-06 | 2022-06-28 | 中国科学院上海药物研究所 | Gpr84受体拮抗剂及其应用 |
| US20210177827A1 (en) | 2017-10-25 | 2021-06-17 | Children`S Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
-
2020
- 2020-12-14 CA CA3164963A patent/CA3164963A1/en active Pending
- 2020-12-14 TW TW109144136A patent/TW202136271A/zh unknown
- 2020-12-14 IL IL293968A patent/IL293968A/en unknown
- 2020-12-14 PE PE2022001093A patent/PE20221786A1/es unknown
- 2020-12-14 EP EP20823813.9A patent/EP4077334A1/en active Pending
- 2020-12-14 US US17/786,268 patent/US20230112499A1/en active Pending
- 2020-12-14 AU AU2020408908A patent/AU2020408908A1/en active Pending
- 2020-12-14 MX MX2022007685A patent/MX2022007685A/es unknown
- 2020-12-14 BR BR112022011237A patent/BR112022011237A2/pt unknown
- 2020-12-14 WO PCT/EP2020/085905 patent/WO2021122415A1/en active Application Filing
- 2020-12-14 JO JOP/2022/0156A patent/JOP20220156A1/ar unknown
- 2020-12-14 CR CR20220291A patent/CR20220291A/es unknown
- 2020-12-14 KR KR1020227024304A patent/KR20220118480A/ko unknown
- 2020-12-14 JP JP2022537545A patent/JP2023508908A/ja active Pending
- 2020-12-14 CN CN202080097024.7A patent/CN115135656B/zh active Active
- 2020-12-14 GE GEAP202016005A patent/GEP20247585B/en unknown
- 2020-12-21 AR ARP200103594A patent/AR120856A1/es unknown
-
2022
- 2022-06-14 EC ECSENADI202247527A patent/ECSP22047527A/es unknown
- 2022-06-15 CO CONC2022/0008338A patent/CO2022008338A2/es unknown
- 2022-06-15 DO DO2022000126A patent/DOP2022000126A/es unknown
- 2022-06-16 CL CL2022001644A patent/CL2022001644A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115135656A (zh) | 2022-09-30 |
| CN115135656B (zh) | 2024-06-14 |
| KR20220118480A (ko) | 2022-08-25 |
| CL2022001644A1 (es) | 2023-02-24 |
| EP4077334A1 (en) | 2022-10-26 |
| WO2021122415A9 (en) | 2022-06-30 |
| GEP20247585B (en) | 2024-01-25 |
| ECSP22047527A (es) | 2022-07-29 |
| JP2023508908A (ja) | 2023-03-06 |
| CR20220291A (es) | 2022-08-10 |
| CA3164963A1 (en) | 2021-06-24 |
| US20230112499A1 (en) | 2023-04-13 |
| MX2022007685A (es) | 2022-07-19 |
| DOP2022000126A (es) | 2022-07-15 |
| CO2022008338A2 (es) | 2022-07-08 |
| AU2020408908A1 (en) | 2022-06-30 |
| WO2021122415A1 (en) | 2021-06-24 |
| AR120856A1 (es) | 2022-03-23 |
| TW202136271A (zh) | 2021-10-01 |
| JOP20220156A1 (ar) | 2023-01-30 |
| BR112022011237A2 (pt) | 2022-08-30 |
| IL293968A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221786A1 (es) | Derivados de furoindazol | |
| MX2020011501A (es) | Compuestos novedosos. | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| AR111242A1 (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak | |
| MX2020000261A (es) | Nuevos compuestos. | |
| AR014886A1 (es) | 4,5-diarilimidazoles 2-substituidos, composiciones farmaceuticas que los contienen y su uso para la manufactura de medicamentos | |
| ES2196772T3 (es) | Compuestos amino ciclicos. | |
| EA201890695A1 (ru) | Новые пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств | |
| IS8056A (is) | Bensoxasínýl-amídósýklópentýl-heterósýklýskir stillar á flakkboða viðtaka | |
| JP2016518385A5 (es) | ||
| AR110443A1 (es) | Inhibidores de histona metiltransferasas | |
| RU2015143000A (ru) | N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств | |
| ES391629A1 (es) | Procedimiento para la obtencion de biguanidas. | |
| MX2016002738A (es) | Compuestos farmaceuticos. | |
| AR110349A1 (es) | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga | |
| PH12020500461A1 (en) | 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation | |
| MX2024005670A (es) | Analogos deuterados de acetil-leucina. | |
| AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
| Salzinger et al. | Some formal characteristics of schizophrenic speech as a measure of social deviance. | |
| IE35434B1 (en) | Benzene derivatives | |
| EA202192032A1 (ru) | Соединения n-ацил-{4-[(4-арилфенил)сульфонилметил]пиперидина} и их терапевтическое применение | |
| AR036508A1 (es) | Antagonistas v del receptor de ccr-3 | |
| RU2015112605A (ru) | Изотопно-обогащенные арилсульфонамидные антагонисты ccr3 | |
| GB912112A (en) | Haloalkyl triazines | |
| GB1068985A (en) | Phenazine derivatives |